サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1072844

デジタルPCR (dPCR) およびリアルタイムPCR (qPCR) の市場規模・シェア・動向分析：製品&サービス・用途・エンドユーザー・地域別の展望・競合戦略・各種区分別の予測 (～2030年)

Digital PCR (dPCR) and Real-time PCR (qPCR) Market Size, Share & Trends Analysis By Product & service, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
デジタルPCR (dPCR) およびリアルタイムPCR (qPCR) の市場規模・シェア・動向分析：製品&サービス・用途・エンドユーザー・地域別の展望・競合戦略・各種区分別の予測 (～2030年)
出版日: 2022年04月27日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のデジタルPCR (dPCR) およびリアルタイムPCR (qPCR) の市場規模は予測期間中8.8%のCAGRで推移し、2030年には113億9,000万米ドルの規模に成長すると予測されています。

高度なPCR技術、投資の拡大、遺伝性疾患や感染症の増加、疾患診断におけるバイオマーカープロファイリングの重要性の高まり、ヒトゲノムプロジェクトの活況などの要因が同市場の成長を推進しています。一方で、qPCRおよびdPCR技術の技術的限界、高価な関連デバイスなどの課題が市場拡大の阻害要因となる可能性があります。

当レポートでは、世界のデジタルPCR (dPCR) およびリアルタイムPCR (qPCR) の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 成長要因・抑制要因・機会・課題の分析
  • COVID-19の影響

第5章 市場変数・見通し

  • SWOT分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • ヒートマップ分析

第6章 世界のdPCRおよびqPCR市場：製品&サービス別

  • qPCR製品&サービス
    • qPCR試薬・消耗品
    • qPCR機器
    • qPCRソフトウェア・サービス
  • dPCR製品&サービス
    • dPCR機器
    • dPCR試薬・消耗品
    • dPCRソフトウェア・サービス

第7章 世界のdPCRおよびqPCR市場：用途別

  • qPCR
    • 臨床
    • 法医学
    • 研究
  • dPCR
    • 臨床
    • 研究
    • 法医学

第8章 世界のdPCRおよびqPCR市場：エンドユーザー別

  • dPCRエンドユーザー
    • 臨床研究機関
    • 法医学ラボ
    • 病院・診断センター
    • 製薬およびバイオテクノロジー企業
    • 研究・学術機関
  • qPCRエンドユーザー
    • 臨床調査機関
    • 法医学ラボ
    • 病院・診断センター
    • 製薬およびバイオテクノロジー企業
    • 研究および学術機関

第9章 世界のdPCRおよびqPCR市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第10章 企業プロファイル

  • Abbott Laboratories
  • Agilent Technologies
  • Analytik Jena AG
  • Becton Dikinson and Company
  • bioMerieux SA
  • Bioneer
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • ELITech Group
  • Enzo Life Sciences, Inc.
  • Eppendorf
  • F. Hoffmann-La Roche, Ltd.
  • Fluidigm Corporation
  • Merck KGaA
  • Meridian Bioscience
  • Promega Corporation
  • QIAGEN N.V.
  • Quidel Corporation
  • Takara Bio
  • Thermo Fisher Scientific
目次
Product Code: BIOT2217

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market projected to be worth USD 11.39 billion by 2030.

According to SPER Market Research, the Digital PCR (dPCR) and Real-time PCR (qPCR) Market estimated to reach USD 11.39 billion by 2030 with a CAGR of 8.8%.

The key fuels for the market escalation are; advanced PCR technologies, growing investments, increasing genetic as well as targeted infectious disease, raising the exploit of biomarkers profiling in the disease diagnosis, and the booming Human Genome project.

Impact of COVID-19 on the Digital PCR (dPCR) and Real-time PCR (qPCR) Market

The COVID-19 outbreak has mainly impacted to the healthcare industry; diagnostic industry is one of them. There is a positive impact in the PCR industries. Digital PCR (dPCR) and Real-time PCR (qPCR) has the importance in the diagnostic and drug discovery. The focus of the companies is to produce digital PCR kits for the diagnosis of the infection.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030

Segments covered By Product & Service, By Application, By End-User, By Region.

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered: Abbott Laboratories, Agilent Technologies, Analytik Jena AG, Becton, Dikinson and Compan, bioMerieux SA, Bioneer, Bio-Rad Laboratories Inc.Dan, aher Corporation, ELITech Group, Enzo Life Sciences, Inc., Eppendorf, F. Hoffmann-La Roche, Ltd., Fluidigm Corporation, Merck KGaA, Meridian Bioscience, Promega Corporation, QIAGEN N.V., Quidel Corporation, Thermo Fisher Scientific, Takara Bio

Driver: growing occurrence of target infectious diseases and genetic disorders

Rising incidence of target infectious diseases and genetic disorders, technological advancements in PCR technologies, increasing investments, funds, and grants, increasing use of biomarker profiling for disease diagnostics, successful completion of the Human Genome Project; are the key drives of the escalation of the market.

Restraint: High device costs coupled with dPCR

Technical limitations of qPCR and dPCR techniques, costly device coupled with dPCR; can resist the escalation of the market.

Opportunity: rising market penetration in emerging countries

Growing market penetration in emerging countries, shift from plant-derived to genome-based drug discovery; offers enormous opportunities to the players in the market.

Challenges:

Adoption and implementation of MIQE guidelines, is the challenge to the market expansion.

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Product & Service:

Based on the Product and Service, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR Products & Services (qPCR Reagents and Consumables, qPCR Instruments, qPCR Software and Services), dPCR Products & Services (dPCR Instruments, dPCR Reagents and Consumables, dPCR Software and Services).

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Application:

Based on the Application, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR Applications (Clinical Applications, Forensic Applications, Research Applications), dPCR Applications (Clinical Applications, Research Applications, Forensic Applications).

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By End-User:

Based on the End-User, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR End User (Clinical Research Organizations, Forensic Laboratories, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes), qPCR End User (Clinical Research Organizations, Forensic Laboratories, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes).

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Region:

North America, dominates the principal share of this market; and this is because of accessibility to research & development funding, growing acceptance of innovative and novel genomic analysis, escalating use of PCR techniques in the clinical diagnostics, forensics, and commercialization of qPCR/dPCR products.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Digital PCR (dPCR) and Real-time PCR (qPCR) Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Product & Service, 2019-2030 (USD Million)

  • 6.1. qPCR Products & Services
    • 6.1.1. qPCR Reagents and Consumables
    • 6.1.2. qPCR Instruments
    • 6.1.3. qPCR Software and Services
  • 6.2. dPCR Products & Services
    • 6.2.1. dPCR Instruments
    • 6.2.2. dPCR Reagents and Consumables
    • 6.2.3. dPCR Software and Services

7. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Application, 2019-2030 (USD Million)

  • 7.1. qPCR Applications
    • 7.1.1. Clinical Applications
    • 7.1.2. Forensic Applications
    • 7.1.3. Research Applications
  • 7.2. dPCR Applications
    • 7.2.1. Clinical Applications
    • 7.2.2. Research Applications
    • 7.2.3. Forensic Applications

8. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By End-User, 2019-2030 (USD Million)

  • 8.1. dPCR End User
    • 8.1.1. Clinical Research Organizations
    • 8.1.2. Forensic Laboratories
    • 8.1.3. Hospitals and Diagnostic Centers
    • 8.1.4. Pharmaceutical and Biotechnology Companies
    • 8.1.5. Research Laboratories and Academic Institutes
  • 8.2. qPCR End User
    • 8.2.1. Clinical Research Organizations
    • 8.2.2. Forensic Laboratories
    • 8.2.3. Hospitals and Diagnostic Centers
    • 8.2.4. Pharmaceutical and Biotechnology Companies
    • 8.2.5. Research Laboratories and Academic Institutes

9. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Agilent Technologies
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Analytik Jena AG
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Becton Dikinson and Company
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. bioMerieux SA
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Bioneer
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Bio-Rad Laboratories Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Danaher Corporation
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. ELITech Group
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Enzo Life Sciences, Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Eppendorf
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. F. Hoffmann-La Roche, Ltd.
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Fluidigm Corporation
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Merck KGaA
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Meridian Bioscience
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Promega Corporation
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. QIAGEN N.V.
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Quidel Corporation
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Takara Bio
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. Thermo Fisher Scientific
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments